View article

Background:

The SWORD trials showed that in participants who achieved virologic suppression taking 3-drug or 4-drug regimens, switching to the 2-drug regimen dolutegravir plus rilpivirine was noninferior in maintaining HIV-1 RNA< 50 copies/mL at the week 48 primary endpoint. We present pooled week 148 analysis results from both studies.

Setting:

SWORD-1: 65 centers, 13 countries; SWORD-2: 60 centers, 11 countries.

Methods:

SWORD-1 and SWORD-2 are identical, open-label, phase III studies. Participants with screening HIV-1 RNA< 50 copies/mL for≥ 6 months; no prior virologic failure; and no documented resistance-associated major protease inhibitor, integrase inhibitor, nucleoside reverse transcriptase inhibitor (NRTI), or non-NRTI mutations or integrase resistance-associated substitution R263K were randomly assigned 1: 1 to switch to once-daily dolutegravir 50 mg plus rilpivirine 25 mg on day 1 …